key: cord-0702590-nck7w04a authors: Ojetti, Veronica; Saviano, Angela; Covino, Marcello; Acampora, Nicola; Troiani, Eliana; Franceschi, Francesco title: COVID-19 and intestinal inflammation: role of fecal calprotectin date: 2020-09-22 journal: Dig Liver Dis DOI: 10.1016/j.dld.2020.09.015 sha: 9f0d6116a92e75f0d4fcc06c093c9af4863a1a4f doc_id: 702590 cord_uid: nck7w04a nan Dear Editor, At the end of January 2020, the World Health Organization (WHO) declared the SARS-Cov-2 (or Coronavirus 19 ) infection a global health emergency [1] . The virus, belonging to the β-Coronaviruses, spreads mainly through the respiratory tract from person to person, using the transmembrane serine protease 2 (TMPRSS2) [2] for S spike-protein priming and the angiotensinconverting-enzyme 2 (ACE2) receptors, receptors sited not only in the pulmonary epithelium but also in others districts such as in the renal and gastrointestinal ones [3] . SARS-Cov-2 infection typically occurs with fever, cough and interstitial pneumonia to more severe pictures of respiratory failure and ARDS [4] . Increasingly, patients experience nausea and vomiting, abdominal pain, anorexia and diarrhea [5] in addition to respiratory symptoms or, in some cases, patients are asymptomatic [1] . Several studies suggest that the virus actively infects the cells of the gastrointestinal district [6] , replicating itself in the epithelium of the small and large intestine [5, 7] and producing an excessive immunological reaction in the host [8] , with the consequent production of many cytokines [interleukin 6 (IL-6) 11, Tumor Necrosis Factor (TNF-alpha) and interferon (INF) -alpha] by activated leukocytes [8, 9] . The latter, especially neutrophils, also produce calprotectin [10] , a calcium and zinc binding protein of the S-100 family of proteins, widely studied in inflammatory bowel disease, which is a useful tool to identify the damage of the intestinal mucosa. Calprotectin is indeed involved in many cellular physiological functions including cellular differentiation, migration, adhesion, and phagocytosis of neutrophils and is considered a positive acute phase protein. Therefore, the presence of calprotectin in the stool is a consequence of the migration of neutrophils into the gastrointestinal tissue due to an infection or an inflammatory process [3, 10] . We conducted an observational study in the Emergency Department (ED) of the A. Gemelli University Hospital Foundation. The primary endpoint of our study was to evaluate the degree of intestinal inflammation by measuring the fecal calprotectin in symptomatic patients with a positive swab for COVID-19 and a radiological imaging of interstitial pneumonia compared to asymptomatic patients with a positive swab for COVID-19 and without evidence of interstitial pneumonia. The secondary endpoint was to identify the potential link between the level of fecal calprotectin and the severity of pulmonary manifestations from COVID-19 (including respiratory failure). Each patient performed a chest x-ray or a chest computed tomography (CT) scan and collected a stool sample analyzed for fecal calprotectin in the Clinical Chemistry laboratory of the hospital. The stool samples were extracted using the DiaSorin LIAISON Q.S.E.T. stool extraction device; measurements were subsequently performed using Liaison Calprotectin assay on a Liaison XL analyzer. The DiaSorin LIAISON Q.S.E.T. calprotectin assay is a sandwich chemiluminescent immunoassay (CLIA) that uses two monoclonal antibodies for capture and detection of calprotectin. Calprotectin was first extracted from stool samples The assay incubates the extracted sample, with the assay buffer and the paramagnetic particles coated with a monoclonal antibody that specifically recognizes the calprotectin heterocomplex. Following incubation, a wash cycle is performed to remove any unbound material. An isoluminol conjugated monoclonal antibody that recognizes calprotectin is then added to the reaction and incubated. The unbound conjugate is removed with a second wash step. Starter reagents are then added, and a flash chemiluminescent reaction started. The light signal is measured by a photomultiplier as relative light units (RLU) and is proportional to the concentration of calprotectin present in the samples. The concentration was expressed in µg/g. The normal value was considered < 50 µg/g. We excluded patients with age <18 years; pregnant women; patients receiving hydroxychloroquine; terminal oncological diseases; patients with heart disease, severe nephropathy and active inflammatory bowel diseases; patients with a history of pulmonary fibrosis, advanced interstitial disease, severe COPD (GOLD 3-4; group C and D); patients on antibiotic therapy or who have taken it in the last month. We compared study variables between patients with normal calprotectin values (≤ 50 µg/g) and patients with elevated calprotectin values. We expressed non parametric variables as absolute numbers (%) and compared by Chi 2 test (with Fisher's test as appropriate); continuous variables are expressed as median [interquartile range] and compared by Mann-Whitney U test while parameters with significant association to an elevated calprotectin values were entered into a logistic regression model in order to individuate independent predictors associated to elevated calprotectin. We considered a p value ≤ 0.05 as statistically significant. We analyzed data by SPSS v25® (IBM, IL, USA). We enrolled a total of 65 consecutive patients (15 women and 50 men) with an age of 38 years old (34-55). They were admitted with a positive swab for COVID-19 to our ED from the 1 st -30 th April 2020. The demographic, clinical features and lab tests of the patients are summarized in Table 1 . Finally, we found that in patients with elevated calprotectin levels, gastrointestinal symptoms were more frequent (9/19 (47.4%) vs. 7/46 (15.2%); p=0.006). No differences were observed as regards other laboratory tests [ Table 1 ]. When these factors were entered into a multivariate logistic regression model, we found that an elevated calprotectin level was independently associated with a pathological chest X ray (OR 11. Patients with Covid-19 infection, may experience both lung involvement than systemic impairment, including gastrointestinal one (documented by an increase of fecal calprotectin) not necessarily associated with gastrointestinal symptoms. In fact, in the population we studied, the gastrointestinal involvement (with high level of fecal calprotectin) occurred also in asymptomatic patients. Moreover, we interestingly found that women had higher calprotectin level compared to men. This is a very important result because Covid-19 infection has usually a more severe presentation in males compared to females. So, this let us think that a male with high calprotectin level could have an even worse prognosis than estimated. Our work provides new insights in understanding the association between lung involvement and gastrointestinal one by SARS-Cov-2. In our idea, the digestive system could be a potential route for Covid-19 infections and the monitoring of intestinal markers of inflammation as calprotectin could help physician know the degree of SARS-Cov-2 infection, the potential progression of it, and the possibility of Covid-19 transmission also by asymptomatic patients. Moreover, new studies are needed to explore this field and to find an easy and simple to collect-marker useful for the follow-up of patients who have had Sars-Cov-2 infection. The Novel Coronavirus (SARS-CoV-2) Epidemic Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Covid-19 and the Digestive System Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases We would like to thank Dr. Teresa De Michele, Dr. Andrea Russo, Dr. Rita Murri, Dr. Massimo Fantoni for their contribution to the realization of this paper.